Phase I small molecule clinical trial share vs Sales growth at constant exchange rates
Phase I small molecule clinical trial share and Sales growth at constant exchange rates worldwide, compared over time.
Change the pair
Compare different indicators
The series
Over time
Global, spaced by time. Both series are in %, so they share one axis; the legend names each line.
Phase I small molecule clinical trial share and Sales growth at constant exchange rates
Unit: % · 5 observations
No figure published for these periods
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Phase I small molecule clinical trial share | 2025 | Actual | 62% |
| Phase I small molecule clinical trial share | 2023 | Actual | 60% |
| Phase I small molecule clinical trial share | 2016 | Actual | 72% |
| Sales growth at constant exchange rates | Q2 2026 | Actual | 17.8% |
| Sales growth at constant exchange rates | Q1 2026 | Actual | 3% |
Source: IQVIA, Roche, Sanofi · CC BY 4.0 · Phase I small molecule clinical trial share · Sales growth at constant exchange rates
Provenance
Where these numbers come from
Phase I small molecule clinical trial share
Percentage of Phase I clinical trial starts that evaluate small molecule drugs.
3 observations in Global · source organisations: IQVIA
Sales growth at constant exchange rates
Percentage change in sales calculated at constant exchange rates over the specified period.
2 observations in Global · source organisations: Roche, Sanofi
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring